Effect of Cimetidine on the Single-Dose PK of IV- Administered MNTX

Completed · Phase 1

Conditions studied: Healthy Adult Subjects

In brief

This open-label study assesses the single-dose pharmacokinetics of intravenously-administered MNTX in healthy adult male and female subjects in the absence of, and in the presence of, orally-administered cimetidine.

Key facts

Study ID

NCT01366378

Run by

Bausch Health Americas, Inc.

People needed

18

Starts

2007-01-01

Expected to finish

2007-02-01

Last updated by the study team

2019-11-27

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy males and females between the ages of 18 and 45
• Subjects who are non-smokers
• Subjects with body weights with range of 154-220 lbs.

You may not qualify if…

• Females who are pregnant or lactating
• Subjects with a history of any clinically significant disease or condition affecting a major organ system
• Subjects with ECG abnormalities
• Subjects who have tested positive for hepatitis B, hepatitis C or HIV
• Subjects who have had a diagnosis of alcohol or substance dependence with the past 12 months
• Subjects with positive urine results for drugs of abuse.

Where it is running

• Progenics Pharmaceuticals, Inc. — Tarrytown, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.